6.17 USD
↘ 0.03 (0.40%)LIVE (AS OF 03:29 PM EDT)
Aclaris Therapeutics, Inc.
ACRSNASDAQ • USD
Market: OPEN
ACRS is currently priced at $6.17. ACRS shows a split signal: technical indicators suggest "Strong Buy" while underlying fundamentals indicate "Sell". Key drivers include a concerning Altman Z-Score in the distress zone, a weak Piotroski F-Score of 1/9, negative Return on Equity, a bullish Golden Cross on the moving averages and bullish moving average alignment. Furthermore, ACRS is currently richly valued, trading at a premium to sector peers across key valuation metrics.
Technical & fundamental data as of Aug 26, 2026.
Open?$6.15
High?$6.31
Low?$5.99
Prev. Close?$6.19
Volume?867.5K
Avg. Volume?1.8M
VWAP?$6.20
Rel. Volume?0.47x
Bid / Ask
Bid?$6.14 × 1.5K
Ask?$6.15 × 300
Spread?$0.01
Midpoint?$6.15
Valuation & Ratios
Market Cap?911.2M
Shares Out?139.8M
Float?121.5M
Float %?86.9%
P/E Ratio?N/A
P/B Ratio?7.31
EPS?-$0.51
Dividend?0.00%
Ex-Dividend?N/A
News
Profile
Aclaris Therapeutics Inc is a clinical-stage biopharmaceutical company. It focuses on developing novel drug candidates for immuno-inflammatory diseases using its proprietary KINect drug discovery platform. The company's pipeline consists of the following key product candidates: Bosakitug (ATI-045), an investigational, novel, humanized anti-TSLP monoclonal antibody being developed for patients with severe asthma, COPD, and chronic rhinosinusitis with nasal polyps; ATI-2138, being developed for the potential treatment of T cell-mediated autoimmune diseases; and ATI-052 and ATI-9494. Additionally, it has an investigational product candidate, Lepzacitinib (ATI-1777), which is being focused upon as a potential treatment for atopic dermatitis and potentially other dermatologic conditions.
Employees
73
Market Cap
911.2M
Industry
PHARMACEUTICAL PREPARATIONS
Website
Listed
2015-10-07
Address
701 LEE ROAD
WAYNE, PA 19087
Phone: 484-324-7933
WAYNE, PA 19087
Phone: 484-324-7933
Technical OutlookStrong Buy
Strong SellNeutralStrong Buy
Long-Term (Tide)?▲ Bullish(+3/3)
Medium-Term (Wave)?▲ Bullish(+2/3)
Short-Term (Ripple)?▼ Bearish(-2/3)
MA Alignment?Golden Alignment
Full Technical Analysis →Fundamental OutlookSell
Strong SellNeutralStrong Buy
F-Score?6
Z-Score?11
Momentum?57
Short Sent.?49
Piotroski F-Score?1/9Weak
Altman Z-Score?0.98Distress
Confidence?62%Moderate
Short InterestHigh
Short % of Float?12.11%High
Short Interest?14.7M
Days to Cover?7.0
Free Float121.5M
Avg Daily Volume2.1M
Settlement Date2026-08-14
Financial Health
Current Ratio?3.46Strong
Quick Ratio?3.46Strong
Cash Ratio?0.68Adequate
Debt/Equity?0.00Low
ValuationFAIRLY VALUEDvs 1 peers + S&P 500
Score58/100
P/E?N/A▾
P/B?7.31FAIR▾
Peers100
S&P26
P/S?110.86HIGH▾
Peers100
S&P3
P/FCF?N/A▾
EV/EBITDA?-10.5CHEAP▾
S&P97
EV/Sales?108.53HIGH▾
Peers100
S&P3
Returns & Efficiency
ROE?-60.8%WEAK▾
S&P3
ROA?-42.2%WEAK▾
S&P3
Cash Flow & Enterprise
FCF?$-62177000
Enterprise Value?$892.0M
Fundamentals ratios updated end of day